Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 680 | 106 | 558 |
| Samples | 346 | 70 | 269 |
| Peptides | 272 | 59 | 219 |
Function
MAPK8IP1 · Mitogen-activated protein kinase 8 interacting protein 1
This gene encodes a regulator of the pancreatic beta-cell function. It is highly similar to JIP-1, a mouse protein known to be a regulator of c-Jun amino-terminal kinase (Mapk8). This protein has been shown to prevent MAPK8 mediated activation of transcription factors, and to decrease IL-1 beta and MAP kinase kinase 1 (MEKK1) induced apoptosis in pancreatic beta cells. This protein also functions as a DNA-binding transactivator of the glucose transporter GLUT2. RE1-silencing transcription factor (REST) is reported to repress the expression of this gene in insulin-secreting beta cells. This gene is found to be mutated in a type 2 diabetes family, and thus is thought to be a susceptibility gene for type 2 diabetes. [provided by RefSeq, May 2011].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 265 amino-acid changes on canonical ENST00000241014 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in MAPK8IP1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in MAPK8IP1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 3/25 12% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 2/26 8% | 0/0 0% |
| Oral Cavity Carcinoma | 3/54 6% | 0/0 0% |
| Endometrial Carcinoma | 6/42 14% | 11/612 2% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Colorectal Carcinoma | 17/143 12% | 48/3239 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 30/1592 2% |
| Melanoma | 2/210 1% | 34/1899 2% |
| Bladder Carcinoma | 0/58 0% | 14/956 1% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 8/810 1% |
| Chondrosarcoma | 1/14 7% | 0/75 0% |
| Cervical Carcinoma | 2/35 6% | 3/422 1% |
| Gastric Carcinoma | 1/74 1% | 17/1809 1% |
| Other Solid Cancers | 4/94 4% | 8/1515 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 18/2550 1% |
| Small Cell Lung Carcinoma | 1/9 11% | 4/752 1% |
| Ewings Sarcoma | 0/63 0% | 2/262 1% |
| Non-Small Cell Lung Carcinoma | 3/304 1% | 7/1390 0% |
| Glioma | 1/52 2% | 11/2127 1% |
| Esophageal Carcinoma | 0/23 0% | 4/769 1% |
| Rhabdomyosarcoma | 1/33 3% | 0/171 0% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Ovarian Carcinoma | 4/109 4% | 1/998 0% |
| Head and Neck Carcinoma | 1/85 1% | 6/1574 0% |
| Hepatocellular Carcinoma | 2/46 4% | 7/2210 0% |
| Other Sarcomas | 0/69 0% | 3/699 0% |
| Breast Carcinoma | 2/144 1% | 10/3264 0% |
| Prostate Carcinoma | 0/13 0% | 7/2105 0% |
Mutation Distribution
Where MAPK8IP1 is mutated · all tissues, split by cell line vs tissue
How many mutations in MAPK8IP1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 680 mutations in MAPK8IP1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|